JP2022554141A5 - - Google Patents

Info

Publication number
JP2022554141A5
JP2022554141A5 JP2022523856A JP2022523856A JP2022554141A5 JP 2022554141 A5 JP2022554141 A5 JP 2022554141A5 JP 2022523856 A JP2022523856 A JP 2022523856A JP 2022523856 A JP2022523856 A JP 2022523856A JP 2022554141 A5 JP2022554141 A5 JP 2022554141A5
Authority
JP
Japan
Prior art keywords
patient
aav vector
promoter
gaa
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022523856A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022554141A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/057081 external-priority patent/WO2021081338A1/en
Publication of JP2022554141A publication Critical patent/JP2022554141A/ja
Publication of JP2022554141A5 publication Critical patent/JP2022554141A5/ja
Withdrawn legal-status Critical Current

Links

JP2022523856A 2019-10-25 2020-10-23 糖原病を治療するための組成物及び方法 Withdrawn JP2022554141A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962926282P 2019-10-25 2019-10-25
US62/926,282 2019-10-25
US202063083349P 2020-09-25 2020-09-25
US63/083,349 2020-09-25
PCT/US2020/057081 WO2021081338A1 (en) 2019-10-25 2020-10-23 Compositions and methods for treating glycogen storage disorders

Publications (2)

Publication Number Publication Date
JP2022554141A JP2022554141A (ja) 2022-12-28
JP2022554141A5 true JP2022554141A5 (cg-RX-API-DMAC7.html) 2023-10-31

Family

ID=75620302

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022523856A Withdrawn JP2022554141A (ja) 2019-10-25 2020-10-23 糖原病を治療するための組成物及び方法

Country Status (14)

Country Link
US (1) US20220387562A1 (cg-RX-API-DMAC7.html)
EP (1) EP4048286A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022554141A (cg-RX-API-DMAC7.html)
KR (1) KR20220105643A (cg-RX-API-DMAC7.html)
CN (1) CN114828858A (cg-RX-API-DMAC7.html)
AU (1) AU2020372429A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022007674A2 (cg-RX-API-DMAC7.html)
CA (1) CA3158281A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022006772A2 (cg-RX-API-DMAC7.html)
IL (1) IL292401A (cg-RX-API-DMAC7.html)
MX (1) MX2022004799A (cg-RX-API-DMAC7.html)
PH (1) PH12022550977A1 (cg-RX-API-DMAC7.html)
TW (1) TWI885000B (cg-RX-API-DMAC7.html)
WO (1) WO2021081338A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240145491A (ko) * 2022-02-03 2024-10-07 아스텔라스 진 테라피스, 인크. 폼페병의 개선된 치료를 위한 조성물 및 방법
CN119790064A (zh) 2022-08-23 2025-04-08 马斯得生物有限公司 Il2变体和包括该il2变体的蛋白复合体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001083695A2 (en) * 2000-04-28 2001-11-08 Xiao Xiao Dna sequences encoding dystrophin minigenes and methods of use thereof
EP1366160B1 (en) * 2000-10-06 2008-07-09 The Regents Of The University Of Michigan Mini-dystrophin nucleic acid and peptide sequences
EP4124346A3 (en) * 2012-06-19 2023-04-19 University of Florida Research Foundation, Inc. Compositions and methods for treating diseases
KR102799163B1 (ko) * 2015-09-17 2025-04-21 더 리서치 인스티튜트 앳 네이션와이드 칠드런스 하스피탈 Galgt2 유전자 치료 방법 및 물질
EP3293260A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
US11338045B2 (en) * 2017-03-17 2022-05-24 Newcastle University Adeno-associated virus vector delivery of a fragment of micro-dystrophin to treat muscular dystrophy
US11597917B2 (en) * 2017-07-06 2023-03-07 The Medical College Of Wisconsin, Inc. In vitro and in vivo enrichment strategy targeting lymphocytes derived from vector transduced HSCs for therapy of disorders
CN111936621B (zh) * 2018-02-05 2025-05-13 奥登茨治疗公司 转录调控元件和它的用途
CA3086942A1 (en) * 2018-02-07 2019-08-15 Genethon Hybrid regulatory elements

Similar Documents

Publication Publication Date Title
US20220331409A1 (en) Factor ix gene therapy
US20250161490A1 (en) Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
AU2020331882B2 (en) Isolated modified VP1 capsid protein of AAV5
JP2021512649A5 (cg-RX-API-DMAC7.html)
CN102227500A (zh) 胆色素原脱氨酶基因治疗
JP2020513811A5 (cg-RX-API-DMAC7.html)
JP2021522173A5 (cg-RX-API-DMAC7.html)
US11891616B2 (en) Transgene cassettes designed to express a human MECP2 gene
EP3495472B1 (en) Recombinant virus products and methods for inhibition of expression of myotilin
CA3248774A1 (en) ANTHANOGENE 3 ASSOCIATED WITH B-LYMPHOMA 2 INVOLVING AN ADENO-ASSOCIATED VIRUS (AAV) VECTOR
JP2023537358A5 (cg-RX-API-DMAC7.html)
CN114466682A (zh) 用于治疗基于肌营养不良蛋白的肌病的靶向外显子44的核酸和包含所述核酸的重组腺相关病毒
EP4536686A1 (en) Peptide-modified aav capsid with enhanced muscle transduction efficiency
JP2023553005A (ja) 末梢ミエリンタンパク質22の発現の阻害のための生成物及び方法
US20260131024A1 (en) Gene therapy for prader willi syndrome
JP2025509262A5 (cg-RX-API-DMAC7.html)
Flotte Adeno-associated virus-mediated gene transfer for lung diseases
JP2022523320A5 (cg-RX-API-DMAC7.html)
JP2025505575A5 (cg-RX-API-DMAC7.html)
WO2025162449A1 (en) Compositions and methods for the treatment of heart disease
CA3236188A1 (en) Aav-idua vector for treatment of mps i
TW202434729A (zh) 含有星狀細胞導向啟動子構築體之合成核酸及其使用方法
HK40118571A (en) Adeno-associated virus vector delivery of micro-dystrophin to treat muscular dystrophy
RU2024125625A (ru) Композиции и способы для оптимизированного лечения болезни помпе
JP2021527418A (ja) ジストログリカノパチーおよびラミニン欠損筋ジストロフィーを治療するための組換えアデノ随伴ウイルス生成物および方法